Clover Health Moves Principal Executive Offices

TL;DR

CLOV moved its HQ to Franklin, TN.

AI Summary

Clover Health Investments Corp. filed an 8-K on July 19, 2024, reporting an event on July 16, 2024. The filing indicates a change in the company's principal executive offices to 3401 Mallory Lane, Suite 210, Franklin, Tennessee 37067. This move from their previous address is the primary event reported.

Why It Matters

A change in principal executive offices can signal operational shifts or strategic decisions regarding the company's central management and administrative functions.

Risk Assessment

Risk Level: low — This filing reports a change of address for the company's principal executive offices, which is a routine administrative event with no immediate financial or operational risk.

Key Players & Entities

• CLOVER HEALTH INVESTMENTS, CORP. (company) — Registrant
• 3401 Mallory Lane, Suite 210, Franklin, Tennessee 37067 (location) — New Principal Executive Offices
• July 16, 2024 (date) — Date of earliest event reported
• July 19, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0001 — stered Class A Common Stock, par value $0.0001 per share CLOV The NASDAQ Stock Market

Filing Documents

• clov-20240716.htm (8-K) — 29KB
• ex991-judgmentapprovings.htm (EX-99.1) — 15KB
• ex991-judgmentapprovings001.jpg (GRAPHIC) — 120KB
• ex991-judgmentapprovings002.jpg (GRAPHIC) — 142KB
• ex991-judgmentapprovings003.jpg (GRAPHIC) — 170KB
• ex991-judgmentapprovings004.jpg (GRAPHIC) — 172KB
• ex991-judgmentapprovings005.jpg (GRAPHIC) — 173KB
• ex991-judgmentapprovings006.jpg (GRAPHIC) — 159KB
• ex991-judgmentapprovings007.jpg (GRAPHIC) — 129KB
• 0001801170-24-000152.txt ( ) — 1642KB
• clov-20240716.xsd (EX-101.SCH) — 2KB
• clov-20240716_lab.xml (EX-101.LAB) — 22KB
• clov-20240716_pre.xml (EX-101.PRE) — 13KB
• clov-20240716_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events Litigation Update On July 16, 2024, the United States District Court for the Middle District of Tennessee docketed a Judgment Approving Settlement of Derivative Actions (the " Judgment ") in the shareholder derivative actions captioned (1) Sun v. Garipalli, et al. , No. 3:21-cv-0311 (M.D. Tenn.); (2) In re: Clover Health Investments Corp. Derivative Litig. , No. 1:21-cv-00191 (D. Del.); (3) In re Clover Health Investments, Corp. Stockholder Derivative Litig. , Index No. 655420/2021 (N.Y. Sup. Ct., N.Y. Cnty.); and (4) Davies v. Garipalli, et al. , No. 2021-1016-SG (Del. Ch.) (the " Shareholder Derivative Actions "). A copy of the Judgment is attached to this Current Report on Form 8-K as Exhibit 99.1. As Clover Health Investments, Corp. has previously disclosed, most recently in its April 4, 2024 Current Report on Form 8-K (the " April 8-K "), the settlement resolves the Shareholder Derivative Actions. Through the docketing of the Judgment, the settlement resolves the Shareholder Derivative Actions in the manner previously disclosed in the April 8-K and the Stipulation and Agreement of Settlement dated as of February 2, 2024 attached thereto.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) List of Exhibits Exhibit No. Description 99.1 Judgment Approving Settlement of Derivative Actions 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Clover Health Investments, Corp. Date: July 19, 2024 By: /s/Karen M. Soares Name: Karen M. Soares Title: General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR